Background: Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≤12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC. Patients and methods: Four hundred eleven refractory mCRC patients with ECOG performance status (PS)≤2 receiving regorafenib, TAS-102 or other treatments were used as developing set. Putative prognostic variables were selected using a random forest model and included in a binary logistic model from which the nomogram was developed. The nomogram was externally validated and its performance was evaluated by examining calibration (how close predictions were to the actual outcome) and discriminative ability (Harrell C index) both on developing (internal validation) and validating (external validation) sets. Results: Four variables were selected and included in the nomogram: PS (P < 0.0001), primary tumor resection (P=0.027), LDH value (P=0.0001) and peritoneal involvement (P=0.081). In the developing set, the nomogram discriminative ability was high (C=0.778), and was confirmed in the validating set (C=0.778), where the overall outcome was better as a consequence of the enrichment in patients receiving regorafenib or TAS-102 (46% versus 34%; P < 0.0001). Conclusions: Our nomogram may be a useful tool to predict the probability of death within 12 weeks in patients with refractory mCRC. Based on four easy-to-collect variables, the 'Colon Life' nomogram and free app for smartphones may improve mCRC patients' selection for later-line therapies and assist researchers for the enrollment in clinical trials in this setting.

Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram / Pietrantonio F.; Miceli R.; Rimassa L.; Lonardi S.; Aprile G.; Mennitto A.; Marmorino F.; Bozzarelli S.; Antonuzzo L.; Tamburini E.; Morano F.; Rossini D.; Battaglin F.; Baretti M.; Berenato R.; Formica V.; Mosconi S.; Petrelli F.; Ghidini M.; Loupakis F.; Spada D.; Cinieri S.; Beretta G.; Falcone A.; de Braud F.; Cremolini C.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - ELETTRONICO. - 28:(2017), pp. 555-561. [10.1093/annonc/mdw627]

Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram

Aprile G.;Antonuzzo L.
Writing – Original Draft Preparation
;
Morano F.;Rossini D.;Formica V.;Spada D.;
2017

Abstract

Background: Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≤12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC. Patients and methods: Four hundred eleven refractory mCRC patients with ECOG performance status (PS)≤2 receiving regorafenib, TAS-102 or other treatments were used as developing set. Putative prognostic variables were selected using a random forest model and included in a binary logistic model from which the nomogram was developed. The nomogram was externally validated and its performance was evaluated by examining calibration (how close predictions were to the actual outcome) and discriminative ability (Harrell C index) both on developing (internal validation) and validating (external validation) sets. Results: Four variables were selected and included in the nomogram: PS (P < 0.0001), primary tumor resection (P=0.027), LDH value (P=0.0001) and peritoneal involvement (P=0.081). In the developing set, the nomogram discriminative ability was high (C=0.778), and was confirmed in the validating set (C=0.778), where the overall outcome was better as a consequence of the enrichment in patients receiving regorafenib or TAS-102 (46% versus 34%; P < 0.0001). Conclusions: Our nomogram may be a useful tool to predict the probability of death within 12 weeks in patients with refractory mCRC. Based on four easy-to-collect variables, the 'Colon Life' nomogram and free app for smartphones may improve mCRC patients' selection for later-line therapies and assist researchers for the enrollment in clinical trials in this setting.
2017
28
555
561
Pietrantonio F.; Miceli R.; Rimassa L.; Lonardi S.; Aprile G.; Mennitto A.; Marmorino F.; Bozzarelli S.; Antonuzzo L.; Tamburini E.; Morano F.; Rossin...espandi
File in questo prodotto:
File Dimensione Formato  
PIIS0923753419319568.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 284.88 kB
Formato Adobe PDF
284.88 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1193611
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 43
social impact